Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.39 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.39 |
| ▸ | LPAR1 | Q92633 | 6/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | ERN1 | O75460 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11436443 | 0.87 | ACHE (0.54) | ACHEPOLBGAAGFERPDE3B | |
| SCHEMBL13681512 | 0.81 | ACHE (0.48) | ACHEPOLBGAAGFERPDE3B | |
| SCHEMBL9064476 | 0.79 | LMNA (0.41) | POLBGAAGFERALDH1A1 | |
| SCHEMBL27439457 | 0.79 | GABRA1 (0.41) | POLBGAAGFERPDE3BPDE3A | |
| SCHEMBL16134099 | 0.78 | ACHE (0.45) | ACHEPOLBGAAGFERPDE3B | |
| SCHEMBL16134103 | 0.78 | POLB (0.46) | ACHEPOLBGAAGFERLPAR1 | |
| SCHEMBL20226996 | 0.78 | ACHE (0.45) | ACHEPOLBGAAGFERPDE3B | |
| SCHEMBL14605789 | 0.78 | ACHE (0.45) | ACHEPOLBGAAPDE3BPDE3A | |
| SCHEMBL31545099 | 0.78 | ACHE (0.45) | ACHEPOLBGAAPDE3BPDE3A | |
| SCHEMBL11974265 | 0.78 | ERN1 (0.50) | ACHEPOLBGAAGFERLPAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090145483-A1 | Novel electroluminescent compounds and organic electroluminescent device suing the same | GRACEL DISPLAY INC. (KR) | 2009-06-11 | — | — | US | disclosed |
| US-20090145483-A1 | Novel electroluminescent compounds and organic electroluminescent device suing the same | GRACEL DISPLAY INC. (KR) | 2009-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090145483-A1 | Novel electroluminescent compounds and organic electroluminescent device suing the same | LEF1, ODC1, AOC2 | ACHE 1498/4885POLB 2825/4885GAA 1318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.